Assessment, diagnosis and management of lower urinary tract symptoms in men

International Journal of Clinical Practice

Volumn 56, Issue 8, 2002, Pages 591-603

  Brown, C T ^a   Das, G ^a  

^a ROYAL COLLEGE OF SURGEONS OF ENGLAND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; FINASTERIDE; PLACEBO; SABAL EXTRACT; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN;

ADULT; AGED; BLADDER DYSFUNCTION; BLADDER NECK STENOSIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DROWSINESS; HEADACHE; HUMAN; MALE; MEDICAL ASSESSMENT; MEDICAL DECISION MAKING; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATISM; QUALITY OF LIFE; RETROGRADE EJACULATION; REVIEW; SEXUAL DYSFUNCTION; SURGICAL TECHNIQUE; SYMPTOM; TRANSURETHRAL RESECTION; UROGENITAL TRACT DISEASE; VERTIGO;

ADRENERGIC ALPHA-ANTAGONISTS; AGED; BALLOON DILATATION; CHOLINERGIC ANTAGONISTS; ENZYME INHIBITORS; HUMANS; LASER SURGERY; MALE; MEDICAL HISTORY TAKING; MICROWAVES; MIDDLE AGED; PHYSICAL EXAMINATION; PROSTATIC HYPERPLASIA; STENTS; TESTOSTERONE 5-ALPHA-REDUCTASE; TRANSURETHRAL RESECTION OF PROSTATE; URINARY BLADDER NECK OBSTRUCTION; URINATION DISORDERS; URODYNAMICS;

EID: 0036774418     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Abrams P. New words for old: lower urinary tract symptoms for 'prostatism'. BMJ 1994; 308: 929-930.
2. Barry MJ, Boyle P, Fourcroy J et al. Epidemiology and natural history of BPH. Proceedings of the third international consultation on BPH. World Health Organisation, 1996.
3. Berry SJ, Coffey DS, Walsh PC. The development of benign prostatic hyperplasia with age. J Urol 1984; 132: 474-478.
4. Hunter DJ. Urinary symptoms: prevalence and severity in British men aged 55 years and over. J Epidemiol Comm Health 1994; 48: 569-575.
5. Madsen F, Bruskewitz R. Clinical manifestations of benign prostatic hyperplasia. Urol Clin North Am 1995; 22(2): 291-298.
6. Roberts RO, Rhodes T, Panser LA et al. Natural history of prostatism: worry and embarrassment from urinary symptoms and health care-seeking behavior. Urology 1994; 43(5): 621-628.
7. Simonsen O, Moller B, Dorflinger T et al. The significance of age on symptoms and urodynamic and cystoscopic findings in benign prostatic hypertrophy. Urol Res 1987; 15(6): 355-358.
8. Lepour H. The pathophysiology of lower urinary tract symptoms in the ageing male population. Br J Urol 1998; 81(suppl 1): 29-33.
9. McNeal JE. Origin and evolution of benign prostatic enlargement. Invest Urol 1978; 15: 340.
10. Shapiro E. Embryologic development of the prostate and receptor subtypes. Urol Clin North Am 1990; 17: 487-493.
11. Lepor H, Tang R, Meretyk S, Shapiro E. Alpha-1 adrenoceptor subtypes in the human prostate. J Urol 1993; 149: 640-642.
12. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol 1984; 132: 474-479.
13. Girman CJ, Jacobsen SJ, Guess HA et al. Natural history of prostatism: relationship among symptoms, prostate volume and peak urinary flow rate. J Urol 1995; 153(5): 1510-1515.
14. Barry MJ, Cockett AT, Holtgrewe HL et al. Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993; 150(2): 351-358.
15. Sanda MG, Beaty IH, Stutzman RE et al. Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994; 152(1): 115-119.
16. Dai WS, Gutai JP, Kuller LH et al. Cigarette smoking and serum sex hormones in men. Am J Epidemiol 1988; 128: 796
17. Daniell HW. Larger prostatic adenomas in obese men with no assocaited increase in obstructive uropathy. J Urol 1993; 149: 315.
18. Gosling JA, Gilpin SA, Dixon JS, Gilpin CJ. Decrease in the autonomic innervation of human detrusor muscle in outflow obstruction. J Urol 1986; 136(2): 501-504.
19. Ameda K, Sullivan MP, Bae RJ, Yalla SV. Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol 1999; 162: 142-146.
20. Abrams PH, Farrar DJ, Turner-Warwick RT et al. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979; 121: 640-642.
21. Emberton M, Neal DE, Black N et al. The effect of prostatectomy on symptom severity and quality of life. Br J Urol 1996; 77(2): 233-247.
22. Barry MJ, Fowler FJ, O'Leary MP et al, and the AUA measurement committee. The American Urological Association symptom index for benign prostatic hyperplasia. J Urol 1992; 148: 1549-1557.
23. Donovan JL, Abrams P, Peters TL et al. The 'ICS-BPH' study: psychometric validity and reliability of the ICS male questionnaire. Br J Urol 1996; 77: 554-562.
24. Hansen BJ, Flyger H, Brasso K et al. Validation of the self-administered Danish Prostate Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. Br J Urol 1995; 76: 451-458.
25. Rosier PF, de Wildt MJ et al. Clinical diagnosis of bladder outlet obstruction in patients with benign prostatic enlargement and lower urinary tract symptoms: development and urodynamic validation of a clinical prostate score for the objective diagnosis of bladder outlet obstruction. J Urol 1996; 155: 1649-1654.
26. Cockett ATK, Khoury S, Aso Y et al. Proceedings of the 2nd international consultation on benign prostatic hyperplasia (BPH). Scientific Communication International, 1993.
27. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guidelines No 8. US DHHS, 1994.
28. Barry MJ, OLeary MP. Advances in benign prostatic hyperplasia. The development and clinical utility of symptom scores. Urol Clin North Am 1995; 22(2): 299-307.
29. Hirst G, Butler J, Lajoie V, Maher P et al. The management of uncomplicated lower urinary tract symptoms in men. Clinical practice guidelines. National Health and Medical Research Council of Australia, 2000.
30. Eckhardt MD, van Venrooij GE et al. Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. J Urol 2001; 166(2): 563-568.
31. Plante M, Corcos J, Gregoire I, Belanger MF. The international prostate symptom score: physician versus self-administration in the quantification of symptomatology. Urology 1996; 47(3): 326-328.
32. el Din KE, Kiemeneny LA et al. Correlation between uroflowmetry, prostate volume, postvoid residual, and lower urinary tract symptoms as measured by the International Prostate Symptom Score. Urology 1996; 48(3): 393-397.
33. Wadie BS, Ibrahim EH et al. The relationship of the International Prostate Symptom Score and objective parameters for diagnosing bladder outlet obstruction. J Urol 2001; 165(1): 32-34.34.
34. el Din KE, Kiemeney LA et al. The correlation between bladder outlet obstruction and lower urinary tract symptoms as measured by the International Prostate Symptom Score. J Urol 1996; 156(3): 1020-1025.
35. Bailey R, Shepherd A, Tribe B. How much information can be obtained from frequency volume charts? Neurourol Urodyn 1990; 9: 382-385.
36. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: a comparative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-247.
37. Young JM, Muscatello DJ, Ward JE. Are men with lower urinary tract symptoms at increased risk of prostate cancer? A systematic review and critique of the available evidence. Br J Urol Int 2000; 85: 1037-1048.
38. Dunsmuir WD, Feneley M, Corry DA et al. The day-to-day variation of residual urine measurement. Br J Urol 1996; 77: 192-193.
39. Bruskewitz RC, Iverson P, Madsen PO. Value of post-void resudual urine determination in evaluation of prostatism. Urology 1982; 20: 602-604.
40. Wasson JH, Reda DJ, Bruskewitz RC et al. A comparison of transurethral surgery with watchful waiting for moderate symptoms of benign prostatic hyperplasia. The Veterans Affairs Cooperative Study Group on transurethral resection of the prostate. N Engl J Med 1995; 332(2): 75-79.
41. de Lacey G, Johnson S, Mee D. Prostatism: how useful is routine imaging of the urinary tract? BMJ 1988; 296: 965-967.
42. Koch WF, el Din KE, de Wildt MJ et al. The outcome of renal ultrasound in the assessment of 556 consecutive patients with benign prostatic hyperplasia. J Urol 1996; 155(1): 186-189.
43. Watanabe H. New concept of BPH: PCAR theory. Prostate 1998; 37: 116-125.
44. Robertson AS, Griffiths C, Neal DE. Conventional urodynamics and ambulatory monitoring in the definition and management of bladder outflow obstruction. J Urol 1996; 155(2): 506-5 11.
45. Neal DE, Ramsden PD, Sharples L. Outcome of elective prostatectomy. BMJ 1989; 87: 323-329.
46. Jensen KM, Jorgensen JB, Mogensen P. Urodynamics in prostatism, II. Prognostic value of pressure-flow study combined with stop-flow test. Scand J Urol Nephrol 1998; (suppl)114: 72-77.
47. Yang Q, Abrams P, Donovan J et al. Transurethral resection or incision of the prostate and other therapies: a survey of treatments for benign prostatic obstruction in the UK. Br J Urol Int 1999; 84(6): 640-645.
48. Ball AJ, Feneley RC, Abrams PH. The natural history of untreated 'prostatism'. Br J Urol 198 1; 53(6): 613-616.
49. Kirby RS. The natural history of benign prostatic hyperplasia: what have we learned in the last decade? Urology 2000; 56(5): 3-6
50. Anderson JB, Roehrborn CG, Schalken JA, Emberton M. The progression of benign prostatic hyperplasia: examining the evidence and determining the risk. Eur Urol 2000; 39(4): 390-399.
51. Isaacs JT. Importance of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate 1990; Suppl 3: 1-7.
52. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicentre clinical trail of 6630 men. J Urol 1994; 15: 1283-1290.
53. Mettlin C, Murphy GP, Babaian RJ. Results of a five-year early prostate cancer detection intervention. American Cancer Society National Prostate Cancer Detection Project. Cancer 1996; 77: 150-159.
54. Rietenberg JBW, Kranse R, Boeken Kruger AE et al. Additional value of the AUA 7 symptoms score in prostate cancer (PC) detection. J Urol J997; 157: 467.
55. Palmer MH. Treatment. In: Urinary continence: assessment and promotion. Maryland: Aspen Publishers, 1996.
56. de la Rosette J, Alivizatos G, Madersbacher G et al. European Association of Urology, Guidelines on Benign Prostatic Hyperplasia 2002; section 4: 29.
57. Cutinha PE, Potts KL, Rosario DJ et al. A prospective audit of the use of a prostate clinic. Br J Urol 1996; 78(5): 733-736.
58. Caine M, Raz S, Zeigler M. Adrenergic and cholinergic receptors in the human prostate, prostatic capsule and bladder neck. Br J Urol 1975; 47: 193-202.
59. Hieble JP. Caine M. Zalaznik E. In vitro characterization of the alpha-adrenoceptors in human prostate. Eur J Pharmacol 1985; 107(2): 111-117.
60. Shapiro E, Hartanto V, Lepor H. The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate 1992; 21(4): 297-307.
61. Chappel CR, Anderson KF, Bono VA et al. Alpha-blockers clinical results. Proc Fourth International Consultation on BPH, Paris, 1997; 610-632.
62. Buzelin JM, Hebert M, Blondin P. Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. Br J Urol 1993; 72(6): 922-927.
63. Buzelin JM, Fonteyne E, Kontturi M et al. Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). European Tamsulosin Study Group. Br J Urol 1997; 80: 597-605.
64. Kirby RS. Profile of doxazosin in the hypertensive man with benign prostatic hyperplasia. Br J Clin Pract Symposium 1994; suppl 74: 23-28.
65. Andersson KE. Alpha1 adrenergic receptor blockade in the male lower urinary tract and other body systems. Scand J Neurol Nephrol 1995; 168(suppl): 13-19.
66. Gormley GJ, Stoner E, Bruskewitz RC et al. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992; 327(17): 1185-1191.
67. Nickel JC, Fradet Y, Boakle RC et al. Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomised controlled trial (the PROSPECT Study). Can Med Assoc J 1996; 155: 1251-1259.
68. Lepor H, Williford W, Barry M et al. The efficacy of terazosin, finasteride or both in benign prostatic hyperplasia. N Engl J Med 1996; 335(8): 533-539.
69. Boyle P, Gould AL, Roehrborn CG. Prostate volume predicts the outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomised clinical trials. Urology 1996; 48: 398-405.
70. Marberger MJ. Long term effects of finsteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled multicentre study. PROWESS Study Group. Urology 1998; 51: 677-695.
71. Carlin BI, Bodner DR, Spirnak JP, Resnick MI. Role of finasteride in the treatment of recurrent hematuria secondary to BPH. Prostate 1997; 15: 180-182.
72. Barsch G, McConnell JD, Mahler C et al. Endocrine treatment of BPH. Proc Fourth International Consultation on BPH, Paris 1997; 573-598.
73. Oesterling JE, Roy J, Agha A et al. Biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group. Urology 1997; 50: 13-18.
74. Andriole GL, Guess HA, Epstein JI et al. Treatment with finasteride preserves usefulness of PSA in the detection of prostate cancer: results of a randomised double-blind, placebo-controlled clinical trial. PLESS Study Group. Urology 1998; 52: 195-201.
75. Debruyn FM, Jardin A, Colloi D et al. Sustained release alfuzosin, finasteride and the combination of both in the treatment of BPH. European ALFIN Study Group. Eur Urol 1998; 34: 169-175.
76. Wilt TJ, Ishani A, Stark G et al. Saw Palmetto extracts for the treatment of BPH: a systematic review. JAMA 1998 280: 1604.
77. Froneberg D, Hedlund PO, Lobel B et al. European Association of Urology: guidelines on the management of benign prostatic hyperplasia. EUA Healthcare Office, 2001.
78. Holtgrewe HL, Ackerman R, Bay-Nielson H et al. Report from the Committee on the Economics of BPH. 3rd International Consultation on BPH. Jersey: Scientific Communication International 1996; 51-70.
79. Mebust WK, Holtgrewe HL, Cockett ATK, Peters PC. Transurethral prostatectomy: a comparative study of 13 participating institutions evaluating 3885 patients. J Urol 1989; 141: 243-247.
80. Mozes B, Cohen YC, Olmer L, Shabtai E. Factors affecting change in quality of life after prostatectomy for benign prostatic hypertrophy: the impact of surgical techniques. J Urol 1996; 155(1): 191-196.
81. Montorsi F, Guazzoni G, Bergamashi F et al. Long-term clinical reliability of transurethral and open prostatectomy for BPH: a term comparison of surgical procedures. Eur Urol 1993; 23: 262-266.
82. Tscholl R, Largo M, Poppinghaus E et al. Incidence of erectile impotence secondary to transurethral resection of benign prostatic hyperplasia, assessed by preoperative and postoperative snap gauge tests. J Urol 1995; 153(5): 1491-1493.
83. McConnell JD, Barry MJ, Bruskewitz RC et al. Benign prostatic hyperplasia: diagnosis and treatment. Clinical Practice Guideline No 8. Rockville, Maryland: US Department of Health and Human Services (AHCPR Publication No. 94-0582) 1994.
84. Ogden CW, Reddy P, Johnson H et al. Sham versus transurethral microwave thermotherapy in patients with symptoms of benign prostatic bladder outflow obstruction. Lancet 1993; 341: 14-17.
85. de Wildt M, Hubregtse M, Ogden C et al. A 12 month study of the placebo effect in transurethral microwave thermotherapy. Br J Urol 1996; 77(2): 221-227.
86. Dahlstrand C, Walden M, Geirsson G, Pettersson S. Transurethral microwave thermotherapy versus transurethral resection for symptomatic benign prostatic obstruction: a prospective randomized study with a 2-year follow-up. Br J Urol 1995; 76(5): 614-618.
87. Chiou RK, Binard JE, Ebersole ME et al. Randomized comparison of balloon dilation and transurethral incision for treatment of symptomatic benign prostatic hyperplasia. J Endourol 1994; 8(3): 221-224.
88. Dixon CM. Lasers for the treatment of benign prostatic hyperplasia. Urol Clin North Am 1995; 22(2): 413-422.
89. Sengor F, Kose O, Yucebas E. A comparative study of laser ablation and transurethral electroresection for benign prostatic hyperplasia: results of a 6-month follow-up. Br J Urol 1996; 78: 398-400.
90. Osterling JE, Defaalco AJ, Kaplan SA. The North American experience with the Urolume endoprosthesis as a treatment for benign prostatic hyperplasia: long term results. Urology 1994; 44: 353.